Twenty-six patients with surface vesical tumor receiving epirubicin are included for prophylaxis of relapse following surgical exeresis.
2
At present, the extent of exeresis, the lymph-node dissection technique and the management of upper respiratory-digestive tract infiltration are still debatable issues.